Insider Buying: GSK plc (LON:GSK) Insider Buys 1,350 Shares of Stock

GSK plc (LON:GSK - Get Free Report) insider Jonathan Symonds purchased 1,350 shares of the stock in a transaction on Friday, June 20th. The stock was acquired at an average price of GBX 1,435 ($19.69) per share, with a total value of £19,372.50 ($26,585.01).

GSK Trading Up 0.0%

Shares of LON:GSK traded up GBX 0.50 ($0.01) during trading on Thursday, reaching GBX 1,395 ($19.14). 12,974,224 shares of the stock were exchanged, compared to its average volume of 14,446,446. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. GSK plc has a 12-month low of GBX 1,242.50 ($17.05) and a 12-month high of GBX 1,678.68 ($23.04). The firm has a market cap of £56.61 billion, a price-to-earnings ratio of 22.53, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The firm's 50-day moving average price is GBX 1,432.03 and its 200 day moving average price is GBX 1,414.17.

GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.62) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, sell-side analysts anticipate that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on GSK. Shore Capital restated a "buy" rating on shares of GSK in a report on Wednesday, April 30th. JPMorgan Chase & Co. restated an "underweight" rating on shares of GSK in a report on Friday, March 28th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, GSK presently has an average rating of "Moderate Buy" and a consensus target price of GBX 1,862.50 ($25.56).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.